MetaCap

AN2 Therapeutics (ANTX) vs BioAge Labs (BIOA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AN2 Therapeutics (ANTX) has outperformed BioAge Labs (BIOA) over the past year, gaining 366.1% versus a loss of 50.5%. BioAge Labs is the larger company by market cap ($196.7 million vs $192.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANTX+366.06%BIOA-50.52%
+502%+213%-77%
Nov 21, 20251 yearNov 20, 2026
ANTX+379.25%BIOA-79.62%
+493%+190%-112%
Sep 23, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANTX versus BIOA key metrics
MetricANTXBIOA
Share price$5.08$4.28
Market cap$192.75M$196.67M
1-day change-2.68%-9.13%
YTD return+345.61%-67.65%
1-year return+366.06%-50.52%
EPS (TTM)$-0.91$-2.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$8.99M
Net income (latest FY)$-35.17M$-80.61M
Operating margin—-1031.46%
Net margin—-896.11%
52-week high$7.19$25.96
52-week low$1.00$4.24
Distance from 52-week high-29.35%-83.51%
Analyst consensusstrong_buybuy
Avg. price target upside+77.17%+572.43%
Average volume289.29K740.06K
Shares outstanding37.94M45.95M
Employees2160
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANTX has outperformed BIOA by 416.6 percentage points over the past year.

About AN2 Therapeutics

ANTX stock →

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

About BioAge Labs

BIOA stock →

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.

Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees

ANTX vs BIOA FAQ

Which is bigger, AN2 Therapeutics or BioAge Labs?

BioAge Labs (BIOA) is larger, with a market capitalization of $196.67M compared with $192.75M for AN2 Therapeutics (ANTX).

Which stock has performed better over the past year, ANTX or BIOA?

ANTX returned +366.06% over the past 12 months, compared with -50.52% for BIOA (price return, excluding dividends). Past performance does not predict future results.

Are AN2 Therapeutics and BioAge Labs in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons